The use of andexanet alfa vs. 4-factor prothrombin complex concentrates in the setting of life-threatening intracranial hemorrhage

Post time 2024-5-3 00:03:17

journal：Blood Coagulation & Fibrinolysis

Authors：Vivian M. Irizarry-Gatell; Michael W. Bacchus; Edward K. De Leo; Yang Zhang; Carrie A. Lagasse; Anna Y. Khanna; Neil S. Harris; Marc S. Zumberg

Published date：2024-4-

DOI：10.1097/mbc.0000000000001279

PDF link：https://journals.lww.com/10.1097/MBC.0000000000001279

Article link：http://dx.doi.org/10.1097/mbc.0000000000001279

Article Source：Ovid Technologies (Wolters Kluwer Health)。

Remark：

Post time 2024-5-3 00:03:18

: This post has been completed
Completed attachments will be deleted within 24 hours.

[Ovid] The use of andexanet alfa vs. 4-factor prothrombin complex concentrates in the setting of life-threatening intracranial hemorrhage

Best Answer

Same Category

Latest Reply

Announcement

Enthusiastic users today

[Ovid] The use of andexanet alfa vs. 4-factor prothrombin complex concentrates in the setting of life-threatening intracranial hemorrhage Copy

Best Answer

Same Category

Latest Reply

Announcement

Enthusiastic users today

[Ovid] The use of andexanet alfa vs. 4-factor prothrombin complex concentrates in the setting of life-threatening intracranial hemorrhage